The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 27, 2024
Filed:
Jun. 16, 2017
Applicant:
Life Technologies Corporation, Carlsbad, CA (US);
Inventors:
Brian Agnew, Eugene, OR (US);
Robert Aggeler, Eugene, OR (US);
Assignee:
Life Technologies Corporation, Carlsbad, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); A61K 9/00 (2006.01); A61K 47/60 (2017.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01); C07K 16/46 (2006.01); C12N 9/24 (2006.01); C12N 15/113 (2010.01); C12P 21/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/468 (2013.01); A61K 9/0021 (2013.01); A61K 47/60 (2017.08); A61K 47/6879 (2017.08); A61K 47/6881 (2017.08); A61K 47/6913 (2017.08); C12N 9/2402 (2013.01); C12N 15/113 (2013.01); C12P 21/005 (2013.01); C12Y 302/01018 (2013.01); C12Y 302/01023 (2013.01); C12Y 302/01096 (2013.01); G01N 33/6854 (2013.01); C07K 2317/10 (2013.01); C07K 2317/31 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/54 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3513 (2013.01);
Abstract
Methods are provided for making bispecific antibodies and antibody conjugates comprising site-specifically cross-linking two or more antibodies, antibody fragments or Fc-fusion proteins. Also provided are compositions and uses for the bispecific antibodies and antibody conjugates. The bispecific antibodies may be used to treat a disease or condition. Also provided are methods for site-specifically conjugating a liposome, an mRNA or an siRNA to an antibody, and uses of the antibody-conjugated liposome, mRNA or siRNA.